11 April 2022
Goodbody Health Inc.
("Goodbody Health", or the "Company")
Goodbody Health subsidiary granted Home Office controlled drugs licence
Goodbody Health (AQSE: GDBY) is pleased to announce that its subsidiary, PhytoVista Laboratories, has been granted a controlled drugs licence that allows the company to handle up to Schedule 1 Controlled Drugs. This comes as the
The FSA have released the list of products associated with a credible Novel Food application and we expect the industry to continue to move to a fully regulated market that the Consumer can trust.
PhytoVista is one of a small number of laboratories accredited by the
Geremy Thomas, Executive Chairman, said: "After significant hard work and investment, we are delighted to be recognised and awarded this highly controlled and regulated licence. PhytoVista continues to be a material part of the Government's commitment to create a compliant, consumer cannabinoid industry."
For further information:
|
Marc Howells Chief Executive Officer Goodbody Health Inc. +44 (0) 20 7971 1255 enquiries@goodbodyhealth.com |
Anne Tew Chief Financial Officer Goodbody Health Inc. +44 (0) 20 7971 1255 enquiries@goodbodyhealth.com
|
|
|
AQSE Corporate Adviser Arden Partners plc Antonio Bossi / George Morgan + 44 (0) 20 7614 5900 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.